In contemporary clinical oncology practice and drug development, the methods for evaluating tumor response are on the cusp of a revolution. Since the World Health Organization (WHO) proposed tumor response classification criteria for assessing the effectiveness of anti-cancer drugs in 1981, this field has undergone several improvements. Notably, th...
Phase II Study of Erdafitinib in Patients with FGFR Amplifications: A Detailed Report Background Dysregulation of Fibroblast Growth Factor Receptor (FGFR) family signaling pathways is widely recognized to be associated with cancer development, progression, and treatment resistance. This study primarily investigates tumors with FGFR1-4 amplification...
Overall Survival and Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Patients Based on PTEN Status Academic Background Prostate cancer is one of the most common malignant tumors among men worldwide and a leading cause of cancer-related deaths. Approximately 10%-20% of prostate cancer patients will develop castration-resistant ...
In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...
Prognostic Model of Pulmonary High-grade Neuroendocrine Carcinoma: Integrating Genomic Analysis and Poly(ADP-ribose) Polymerase-1 Expression Research Background High-grade neuroendocrine carcinoma (HGNEC) of the lung is a highly aggressive cancer with significant biological complexity. Despite its association with Notch pathway activation and inact...
Ovarian cancer is one of the most common and deadly tumor types in women. In recent years, Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown encouraging clinical results in the treatment of ovarian cancer. Numerous studies have found that patients with homologous recombination deficiency (HRD) benefit more from PARPi treatment. Therefore, ...
Scientific Research Report Background Introduction Breast cancer is the most commonly diagnosed cancer worldwide among both men and women, and it is the leading cause of cancer-related deaths in women. The standard treatment for early-stage breast cancer usually involves surgery and (neo)adjuvant chemotherapy and/or endocrine therapy, aiming to eli...
Academic Report for the Paper Titled “Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients with Advanced Prostate Cancer from Latin America: Challenges and Future Approaches” Background Prostate cancer is one of the most common cancers among men in Latin America and the Caribbean (LAC). According to the 2020 Glo...
Latest Research in Lung Cancer Genomics: Analysis of Circulating Tumor DNA Detection in Non-Small Cell Lung Cancer Background and Motivation In recent years, the treatment of non-small cell lung cancer (NSCLC) has seen significant changes due to the success of targeted therapies. The National Comprehensive Cancer Network guidelines recommend extens...
Cross-Cancer Study Reveals Biallelic Inactivation of MUTYH and Base Excision Repair Defects in Different Types of Solid Tumors Research Background In daily life, cells are often exposed to endogenous and exogenous oxidative stress, originating from by-products of cellular respiration and various external compounds. MUTYH is a key component of the b...